Navellier & Associates Inc. Invests $3.07 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Navellier & Associates Inc. purchased a new position in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 178,745 shares of the biotechnology company’s stock, valued at approximately $3,065,000.

A number of other hedge funds also recently modified their holdings of ADMA. State Street Corp lifted its holdings in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. Perpetual Ltd acquired a new position in ADMA Biologics in the fourth quarter valued at $62,300,000. Lord Abbett & CO. LLC acquired a new position in ADMA Biologics in the third quarter valued at $61,858,000. Allspring Global Investments Holdings LLC lifted its holdings in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after buying an additional 2,613,482 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in ADMA Biologics by 785.7% in the third quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock valued at $23,872,000 after buying an additional 1,059,394 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Trading Down 1.5 %

ADMA opened at $15.84 on Friday. ADMA Biologics, Inc. has a 1-year low of $5.08 and a 1-year high of $23.64. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The company has a market cap of $3.74 billion, a P/E ratio of 56.57 and a beta of 0.75. The company has a fifty day moving average price of $17.03 and a two-hundred day moving average price of $17.88.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several recent analyst reports. Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright boosted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.